Cargando…

The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy

Previous studies assessing the prevalence of COVID-19 sequelae in children have included either a small number of children or a short follow-up period, or have only focused on hospitalized children. We investigated the prevalence of persistent symptoms amongst children and assessed the risk factors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonsenso, Danilo, Pazukhina, Ekaterina, Gentili, Carolina, Vetrugno, Luigi, Morello, Rosa, Zona, Margherita, De Matteis, Alessia, D’Ilario, Federico, Lanni, Roberta, Rongai, Teresa, del Balzo, Patrizia, Fonte, Maria Teresa, Valente, Michele, De Rose, Cristina, Munblit, Daniel, Sigfrid, Louise, Valentini, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692851/
https://www.ncbi.nlm.nih.gov/pubmed/36431250
http://dx.doi.org/10.3390/jcm11226772
_version_ 1784837373193879552
author Buonsenso, Danilo
Pazukhina, Ekaterina
Gentili, Carolina
Vetrugno, Luigi
Morello, Rosa
Zona, Margherita
De Matteis, Alessia
D’Ilario, Federico
Lanni, Roberta
Rongai, Teresa
del Balzo, Patrizia
Fonte, Maria Teresa
Valente, Michele
De Rose, Cristina
Munblit, Daniel
Sigfrid, Louise
Valentini, Piero
author_facet Buonsenso, Danilo
Pazukhina, Ekaterina
Gentili, Carolina
Vetrugno, Luigi
Morello, Rosa
Zona, Margherita
De Matteis, Alessia
D’Ilario, Federico
Lanni, Roberta
Rongai, Teresa
del Balzo, Patrizia
Fonte, Maria Teresa
Valente, Michele
De Rose, Cristina
Munblit, Daniel
Sigfrid, Louise
Valentini, Piero
author_sort Buonsenso, Danilo
collection PubMed
description Previous studies assessing the prevalence of COVID-19 sequelae in children have included either a small number of children or a short follow-up period, or have only focused on hospitalized children. We investigated the prevalence of persistent symptoms amongst children and assessed the risk factors, including the impact of variants. A prospective cohort study included children (≤18 years old) with PCR-confirmed SARS-CoV-2 infection. The participants were assessed via telephone and face-to-face visits at 1–5, 6–9 and 12 or more months post-SARS-CoV-2 diagnosis using the ISARIC COVID-19 follow-up survey. Of the 679 children enrolled, 51% were female; 488 were infected during the wild virus wave, and 29 were infected with the Alpha, 42 with the Delta and 120 with the Omicron variants. Fatigue (19%), headache (12%), insomnia (7.5%), muscle pain (6.9%) and confusion with concentration issues (6.8%) were the most common persistent symptoms. Families reported an overall improvement over time, with 0.7% of parents interviewed at 12 months or more of the follow-up period reporting a poor recovery. Patients that had not recovered by 6–9 months had a lower probability of recovering during the next follow-up period. Children infected with a variant or the wild virus had an overall similar rate of persistent symptoms (although the pattern of reported symptoms differed significantly) and recovery rates. Conclusions: Recovery rates after SARS-CoV-2 infection improved as time passed from the initial infection, ranging from 4% of children having poor recovery at 1–5 months’ follow-up to 1.3% at 6–9 months and 0.7% at 12 months. The patterns of persistence changed according to the variants involved at the time of infection. This study reinforces that a subgroup of children develop long-lasting persistent symptoms and highlights the need for further studies investigating the reasons behind the development of PCC.
format Online
Article
Text
id pubmed-9692851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96928512022-11-26 The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy Buonsenso, Danilo Pazukhina, Ekaterina Gentili, Carolina Vetrugno, Luigi Morello, Rosa Zona, Margherita De Matteis, Alessia D’Ilario, Federico Lanni, Roberta Rongai, Teresa del Balzo, Patrizia Fonte, Maria Teresa Valente, Michele De Rose, Cristina Munblit, Daniel Sigfrid, Louise Valentini, Piero J Clin Med Article Previous studies assessing the prevalence of COVID-19 sequelae in children have included either a small number of children or a short follow-up period, or have only focused on hospitalized children. We investigated the prevalence of persistent symptoms amongst children and assessed the risk factors, including the impact of variants. A prospective cohort study included children (≤18 years old) with PCR-confirmed SARS-CoV-2 infection. The participants were assessed via telephone and face-to-face visits at 1–5, 6–9 and 12 or more months post-SARS-CoV-2 diagnosis using the ISARIC COVID-19 follow-up survey. Of the 679 children enrolled, 51% were female; 488 were infected during the wild virus wave, and 29 were infected with the Alpha, 42 with the Delta and 120 with the Omicron variants. Fatigue (19%), headache (12%), insomnia (7.5%), muscle pain (6.9%) and confusion with concentration issues (6.8%) were the most common persistent symptoms. Families reported an overall improvement over time, with 0.7% of parents interviewed at 12 months or more of the follow-up period reporting a poor recovery. Patients that had not recovered by 6–9 months had a lower probability of recovering during the next follow-up period. Children infected with a variant or the wild virus had an overall similar rate of persistent symptoms (although the pattern of reported symptoms differed significantly) and recovery rates. Conclusions: Recovery rates after SARS-CoV-2 infection improved as time passed from the initial infection, ranging from 4% of children having poor recovery at 1–5 months’ follow-up to 1.3% at 6–9 months and 0.7% at 12 months. The patterns of persistence changed according to the variants involved at the time of infection. This study reinforces that a subgroup of children develop long-lasting persistent symptoms and highlights the need for further studies investigating the reasons behind the development of PCC. MDPI 2022-11-16 /pmc/articles/PMC9692851/ /pubmed/36431250 http://dx.doi.org/10.3390/jcm11226772 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Buonsenso, Danilo
Pazukhina, Ekaterina
Gentili, Carolina
Vetrugno, Luigi
Morello, Rosa
Zona, Margherita
De Matteis, Alessia
D’Ilario, Federico
Lanni, Roberta
Rongai, Teresa
del Balzo, Patrizia
Fonte, Maria Teresa
Valente, Michele
De Rose, Cristina
Munblit, Daniel
Sigfrid, Louise
Valentini, Piero
The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
title The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
title_full The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
title_fullStr The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
title_full_unstemmed The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
title_short The Prevalence, Characteristics and Risk Factors of Persistent Symptoms in Non-Hospitalized and Hospitalized Children with SARS-CoV-2 Infection Followed-Up for up to 12 Months: A Prospective, Cohort Study in Rome, Italy
title_sort prevalence, characteristics and risk factors of persistent symptoms in non-hospitalized and hospitalized children with sars-cov-2 infection followed-up for up to 12 months: a prospective, cohort study in rome, italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692851/
https://www.ncbi.nlm.nih.gov/pubmed/36431250
http://dx.doi.org/10.3390/jcm11226772
work_keys_str_mv AT buonsensodanilo theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT pazukhinaekaterina theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT gentilicarolina theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT vetrugnoluigi theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT morellorosa theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT zonamargherita theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT dematteisalessia theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT dilariofederico theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT lanniroberta theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT rongaiteresa theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT delbalzopatrizia theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT fontemariateresa theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT valentemichele theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT derosecristina theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT munblitdaniel theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT sigfridlouise theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT valentinipiero theprevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT buonsensodanilo prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT pazukhinaekaterina prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT gentilicarolina prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT vetrugnoluigi prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT morellorosa prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT zonamargherita prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT dematteisalessia prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT dilariofederico prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT lanniroberta prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT rongaiteresa prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT delbalzopatrizia prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT fontemariateresa prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT valentemichele prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT derosecristina prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT munblitdaniel prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT sigfridlouise prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly
AT valentinipiero prevalencecharacteristicsandriskfactorsofpersistentsymptomsinnonhospitalizedandhospitalizedchildrenwithsarscov2infectionfollowedupforupto12monthsaprospectivecohortstudyinromeitaly